Concordance Between Persons with Multiple Sclerosis and Treating Physician on Medication Effects and Health Status

Efrat Neter1, Lea Glass-Marmor2, Loren Haiien2

  • 1Department of Behavioral Sciences, Ruppin Academic Center, Emeq Hefer, Israel.

Abstract

Insights

Physician and patient agreement on multiple sclerosis (MS) treatment effects is key for medication adherence. Studies show good communication leads to better treatment persistence.

Area of Science:

  • Neurology
  • Clinical Research
  • Patient-Reported Outcomes

Background:

  • Expanding treatment options for multiple sclerosis (MS) necessitate alignment on medication effects.
  • Physician-patient agreement is crucial for medication persistence and adherence in MS management.

Purpose of the Study:

  • To evaluate the level of agreement between physicians and persons with MS (PwMS) regarding medication effects.
  • To assess physician-patient concordance on perceived health status in MS patients.

Main Methods:

  • A cross-sectional study involving 71 persons with MS (PwMS).
  • Data collected included patient satisfaction (Treatment Satisfaction Questionnaire for Medication), treatment intentions, and global health perception.
  • Physicians evaluated medication response and global health status.

Main Results:

  • Moderate concordance (rS=0.50) was found between PwMS and physicians on medication effectiveness.
  • Strong concordance (rS=0.57) observed for health status, and moderate inverse concordance (rS=-0.58) for EDSS scores.
  • These findings indicate significant agreement in patient and physician assessments.

Conclusions:

  • Significant concordance highlights effective physician-patient communication in MS care.
  • This alignment may positively influence medication adherence and treatment persistence.
  • Improved communication strategies can enhance management of multiple sclerosis.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
53
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
49
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
134
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
47
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
46
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.2K